New CEO Leads Terumo BCT's Ambition to Shape the Future of Blood and Cell Technologies in Healthcare Antoinette Gawin Focuses on Terumo BCT’s Potential to Treat Disease and Play a Greater Role in Cell Therapy and Regenerative Medicine—Serving More Patient

April 1, 2019

LAKEWOOD, Colo., USA - April 1, 2019 - Antoinette Gawin is expanding Terumo BCT, a biomedical company, beyond its heritage in working with blood centers and hospitals to serve rapidly growing areas of healthcare, such as cell therapy technologies and regenerative medicine. Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas. As President and Chief Executive Officer, Gawin will oversee the company with nearly $1 billion in revenue and 7,000 associates supporting customers in 130 countries.

"Terumo BCT has been passionately engaged in enabling access to blood and cells around the world. Our innovations automate complex processes and help researchers and clinicians unlock the healing potential of an individual's genetic material," Gawin said. "We must diversify our portfolio to fund continued innovation in this cost-conscious healthcare environment and remain relevant to our customers."

- Antoinette Gawin, President and CEO, Terumo BCT

Strategies include embedding the company's products in the cell therapy manufacturing process, increasing the awareness of therapeutic apheresis as a treatment to address autoimmune diseases, building infrastructure in growth geographies and expanding beyond devices into patient data management and services. These efforts increase Terumo BCT's ability to influence healthcare standards and reach more patients.

Gawin succeeds David Perez, who has led the company for 20 years and will continue until June 2019 on the board of directors for Terumo Corporation, parent company of Terumo BCT. Gawin is now one of three women serving the Terumo Corporation as executive officers. This progressive Tokyo-based company has been contributing to society through healthcare for nearly 100 years.

"During the past seven months, Antoinette and I have worked closely to ensure a smooth and world-class transition of leadership. It has been an honor and a privilege to lead and serve Terumo BCT. Over my 20-year tenure, our team has continued to grow, innovate and diversify the company through our passionate commitment to our mission, our associates, our customers and to the patients we serve, who are the ultimate beneficiary of all we do. I am excited for Antoinette as she assumes the leadership of Terumo BCT, and I know without a doubt she will continue to build on our historical legacy and take us to new heights of success for years to come."

- David Perez

Diverse Perspectives

Gawin values all aspects of diversity and believes diversity is a foundation for patient-centered innovation. These values are reflected in her passionate commitment to patients and drive her interest in changing policy and practices to increase access to healthcare technologies. Gawin has brought experience in public policy and her perspective as a global citizen to nonprofit organizations that promote equitable access to healthcare, education and clean water.

Gawin joined Terumo BCT in 2016 in the role of executive vice president, global commercial, bringing nearly 30 years' experience directing diverse global teams and transformational change across Baxter and GE, with global leadership roles at GE Healthcare Technologies, GE Industrial and Power Systems, GE Information Services and GE Financial Services. She holds a master's degree in health policy from DePaul University and bachelor's degrees in economics and English from the University of Michigan.

"Under David's leadership, the company grew revenue almost sixfold, nearing $1 billion, and introduced multiple innovative products that have fundamentally changed and improved blood transfusion and cellular therapies. David and I share the belief that Antoinette is the right person to lead Terumo BCT into the future. She is an outstanding leader with highly valuable experience and a strong track record of delivering growth and driving performance in healthcare."

- Shinjiro Sato, President and CEO of Terumo Corporation, Terumo BCT's parent company

About Terumo BCT

Terumo BCT, a global leader in blood component, therapeutic apheresis and cell therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

https://www.terumobct.com/

Media Contact

Corporate Communication Dept., Terumo Corporation

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

Print
T
O
P